CTSC and cancer: Taken together, these findings suggest that DPP1 is an attractive therapeutic target for a number of NSP-mediated pathologies, and DPP1 inhibition is a promising avenue for the treatment of diseases in which neutrophilic inflammation is central to the pathology, such as chronic inflammatory diseases, autoimmune diseases, and cancer.